GLP-1 Pricing
Reuters reports Novo Nordisk is leaning into the “patients as consumers” shift with a new discounted subscription plan for U.S. self-pay Wegovy users. The concrete numbers: injection pens at $329/month (3 months), $299 (6 months), and $249 (12 months) versus the usual $349 — a 6% to 29% reduction. It’s being distributed through telehealth partners like Ro, WeightWatchers, and LifeMD, with more expected to join. Strategically, this is Novo defending share against Lilly’s Zepbound pricing ladder and trying to pull patients away from compounded copies. The risk is margin compression turning into an actual price war — but the bigger story is that GLP-1s are now being sold like consumer subscriptions.
Source: Reuters
FDA Approval
After an FDA rejection last September over manufacturing concerns, Biogen has now secured approval for a high-dose regimen of Spinraza (nusinersen) in spinal muscular atrophy. The simplified loading schedule is the key: instead of four induction doses of 12mg, new patients receive two 50mg loading doses 14 days apart, followed by 28mg maintenance injections every four months. BioSpace frames it as a “bridge” move to stabilize a franchise that fell below $1.55B in 2025 (after peaking at $2.097B in 2019). This is what lifecycle management looks like when competition (Evrysdi, gene therapy) is already in the room.
Source: BioSpace
Regulatory Calendar
The biotech market doesn’t move on “good science” — it moves on calendar catalysts. BioSpace rounds up six FDA decisions to watch in Q2 2026, a useful lens if you’re tracking volatility rather than mechanism diagrams. The through-line is familiar: label expansions, manufacturing readiness, and whether regulators accept real-world endpoints when trials are messy. It’s also a reminder that in 2026, many of the biggest “binary” moments are no longer for shiny first-in-class assets, but for pragmatic upgrades: dosing, delivery, and post-market evidence.
Source: BioSpace